<?xml version="1.0" encoding="UTF-8"?>
<p>On April 26, 2009, the United States Government declared a public health emergency in response to the threat posed by the 2009 H1N1 influenza virus, A(H1N1)pdm09 [
 <xref ref-type="bibr" rid="B1">1</xref>]. This declaration triggered the Centers for Disease Control and Prevention (CDC) to ship large quantities of medical provisions from the Strategic National Stockpile (SNS) to state health departments around the nation in an effort to mitigate and control outbreaks of the novel virus. Included in this shipment were 11 million regimens of antiviral drugs (two neuraminidase inhibitors, oseltamivir and zanamivir), which were later accompanied by new federal guidance on the recommended clinical use of these drugs during the pandemic [
 <xref ref-type="bibr" rid="B2">2</xref>,
 <xref ref-type="bibr" rid="B3">3</xref>]. These events prompted state and local health departments to make decisions regarding how and where publicly purchased antivirals would be used in their communities to treat ill persons and slow the spread of disease.
</p>
